WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG’s president and chief executive officer, will provide an update on the company followed by a breakout session at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 at 8:00 a.m. Pacific Time. During the presentation and breakout session, the company’s business, regulatory status, strategy and growth prospects will be discussed.
A live audio webcast of the company’s presentation and the following breakout session along with the accompanying slide presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 15, 2015.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG and its maternal health division, Lumara HealthTM, is to bring to market therapies that provide clear benefits and improve patients’ lives. In addition to continuing to pursue opportunities to make new advancements in patients’ health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies. For additional company information, please visit www.amagpharma.com.
CONTACT: AMAG Pharmaceuticals, Inc.
Katie Payne, 617-498-3303
AMAG Pharmaceuticals, Inc.